Dexamethasone Intravitreal Implant Is Active at the Molecular Level Eight Weeks after Implantation in Experimental Central Retinal Vein Occlusion

Dexamethasone Intravitreal Implant Is Active at the Molecular Level Eight Weeks after Implantation in Experimental Central Retinal Vein Occlusion

Central retinal vein occlusion (CRVO) is a visually disabling condition resulting from a thrombus in the major outflow vessel of the eye. The inflammatory response in CRVO is effectively treated with a dexamethasone (DEX) intravitreal implant. Uncovering the proteome changes following DEX implant in...

Full description

Bibliographic Details
Main Authors: Lasse Jørgensen Cehofski, Anders Kruse, Mads Odgaard Mæng, Benn Falch Sejergaard, Anders Schlosser, Grith Lykke Sorensen, Jakob Grauslund, Bent Honoré, Henrik Vorum
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Molecules
Subjects:
retina
retinal vein occlusion
mass spectrometry
proteomics
proteome
dexamethasone
Online Access:https://www.mdpi.com/1420-3049/27/17/5687

Internet

https://www.mdpi.com/1420-3049/27/17/5687

Similar Items